Apremilast in psoriasis–a prospective real‐world study
Background Apremilast is a novel oral phosphodiesterase‐4 inhibitor approved for psoriasis
treatment. Randomized trials have documented its efficacy and safety, but data on real …
treatment. Randomized trials have documented its efficacy and safety, but data on real …
[PDF][PDF] Apremilast in psoriasis–a prospective real-world study
I Vujic, R Herman, M Sanlorenzo, C Posch, B Monshi… - 2017 - researchgate.net
Background Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for psoriasis
treatment. Randomized trials have documented its efficacy and safety, but data on real-world …
treatment. Randomized trials have documented its efficacy and safety, but data on real-world …
Apremilast in psoriasis-a prospective real-world study.
I Vujic, R Herman, M Sanlorenzo, C Posch, B Monshi… - 2018 - mediatum.ub.tum.de
BACKGROUND: Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for
psoriasis treatment. Randomized trials have documented its efficacy and safety, but data on …
psoriasis treatment. Randomized trials have documented its efficacy and safety, but data on …
Apremilast in psoriasis-a prospective real-world study
I Vujic, R Herman, M Sanlorenzo… - Journal of the …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for psoriasis
treatment. Randomized trials have documented its efficacy and safety, but data on real-world …
treatment. Randomized trials have documented its efficacy and safety, but data on real-world …
Apremilast in psoriasis–a prospective real-world study.
I Vujic, R Herman, M Sanlorenzo… - Journal of the …, 2018 - search.ebscohost.com
Background Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for psoriasis
treatment. Randomized trials have documented its efficacy and safety, but data on real-world …
treatment. Randomized trials have documented its efficacy and safety, but data on real-world …
[引用][C] Apremilast in psoriasis-a prospective real-world study
I Vujic, R Herman, M Sanlorenzo, C Posch… - Journal of the …, 2017 - cir.nii.ac.jp
Apremilast in psoriasis - a prospective real-world study | CiNii Research CiNii 国立情報学研究所
学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を …
学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を …
Apremilast in psoriasis-a prospective real-world study.
I Vujic, R Herman, M Sanlorenzo, C Posch… - Journal of the …, 2017 - europepmc.org
Background Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for psoriasis
treatment. Randomized trials have documented its efficacy and safety, but data on real-world …
treatment. Randomized trials have documented its efficacy and safety, but data on real-world …